Hope in the Long Road Toward the Development of a Therapeutic Human Papillomavirus Vaccine.
A pool of long synthetic peptides derived from HPV16 proteins induce objective partial or complete histologic regression of lesions in more than 50% of patients with high-grade vulvar (VuVIN3) and vaginal intraepithelial neoplasia (VaIN3). The intensity of T-cell response induced by the vaccine was correlated with clinical response. Clin Cancer Res; 22(10); 2317-9. ©2016 AACRSee related article by van Poelgeest et al., p. 2342.